Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Miriam Royo is active.

Publication


Featured researches published by Miriam Royo.


Journal of Medicinal Chemistry | 2009

Adenosine A2A Receptor-Antagonist/Dopamine D2 Receptor-Agonist Bivalent Ligands as Pharmacological Tools to Detect A2A-D2 Receptor Heteromers

Aroa Soriano; Rubén Ventura; Anabel Molero; Rob Hoen; Vicent Casadó; Antoni Cortés; Francesca Fanelli; Fernando Albericio; Carmen Lluis; Rafael Franco; Miriam Royo

Adenosine A(2A) (A(2A)R) and dopamine D(2) (D(2)R) receptors mediate the antagonism between adenosinergic and dopaminergic transmission in striatopallidal GABAergic neurons and are pharmacological targets for the treatment of Parkinsons disease. Here, a family of heterobivalent ligands containing a D(2)R agonist and an A(2A)R antagonist linked through a spacer of variable size was designed and synthesized to study A(2A)R-D(2)R heteromers. Bivalent ligands with shorter linkers bound to D(2)R or A(2A)R with higher affinity than the corresponding monovalent controls in membranes from brain striatum and from cells coexpressing both receptors. In contrast, no differences in affinity of bivalent versus monovalent ligands were detected in experiments using membranes from cells expressing only one receptor. These findings indicate the existence of A(2A)R-D(2)R heteromers and of a simultaneous interaction of heterobivalent ligands with both receptors. The cooperative effect derived from the simultaneous interaction suggests the occurrence of A(2A)R-D(2)R heteromers in cotransfected cells and in brain striatum. The dopamine/adenosine bivalent action could constitute a novel concept in Parkinsons disease pharmacotherapy.


Trends in Parasitology | 2011

Protein translation in Plasmodium parasites.

Katherine E. Jackson; Saman Habib; Magali Frugier; Rob Hoen; Sameena Khan; James S. Pham; Lluís Ribas de Pouplana; Miriam Royo; Manuel A. S. Santos; Amit Sharma; Stuart A. Ralph

The protein translation machinery of the parasite Plasmodium is the target of important anti-malarial drugs, and encompasses many promising targets for future drugs. Plasmodium parasites have three subcellular compartments that house genomes; the nucleus, mitochondrion and apicoplast, and each requires its own compartmentalized transcription and translation apparatus for survival. Despite the availability of the complete genome sequence that should reveal the requisite elements for all three compartments, our understanding of the translation machineries is patchy. We review what is known about cytosolic and organellar translation in Plasmodium and discuss the molecules that have been identified through genome sequencing and post-genomic analysis. Some translation components are yet to be found in Plasmodium, whereas others appear to be shared between translationally active organelles.


Tetrahedron Letters | 1998

Solid-phase synthesis of diketopiperazines, useful scaffolds for combinatorial chemistry

Montserrat del Fresno; Jordi Alsina; Miriam Royo; George Barany; Fernando Albericio

Abstract Diketopiperazines, which are cyclic dipeptides, are often formed by a side reaction of solid-phase peptide synthesis. Using the new “Backbone Amide Linker,” this chemistry can be conveniently harnessed for the intentional preparation of diketopiperazines. These products will be useful scaffolds for combinatorial chemistry, since they incorporate three different points of diversity: both amino acid side-chains and one (of the two) amide bonds.


Diabetes | 2007

Oral Insulin-Mimetic Compounds That Act Independently of Insulin

Silvia Garcia-Vicente; Francesc Yraola; Luc Marti; Elena González-Muñoz; María José García-Barrado; Carles Cantó; Anna Abella; S. Bour; Rafael Artuch; Cristina Sierra; Nuria Brandi; Christian Carpéné; Julio Moratinos; Marta Camps; Manuel Palacín; Xavier Testar; Anna Gumà; Fernando Albericio; Miriam Royo; Alec Mian; Antonio Zorzano

The hallmarks of insulin action are the stimulation and suppression of anabolic and catabolic responses, respectively. These responses are orchestrated by the insulin pathway and are initiated by the binding of insulin to the insulin receptor, which leads to activation of the receptor’s intrinsic tyrosine kinase. Severe defects in the insulin pathway, such as in types A and B and advanced type 1 and 2 diabetes lead to severe insulin resistance, resulting in a partial or complete absence of response to exogenous insulin and other known classes of antidiabetes therapies. We have characterized a novel class of arylalkylamine vanadium salts that exert potent insulin-mimetic effects downstream of the insulin receptor in adipocytes. These compounds trigger insulin signaling, which is characterized by rapid activation of insulin receptor substrate-1, Akt, and glycogen synthase kinase-3 independent of insulin receptor phosphorylation. Administration of these compounds to animal models of diabetes lowered glycemia and normalized the plasma lipid profile. Arylalkylamine vanadium compounds also showed antidiabetic effects in severely diabetic rats with undetectable circulating insulin. These results demonstrate the feasibility of insulin-like regulation in the complete absence of insulin and downstream of the insulin receptor. This represents a novel therapeutic approach for diabetic patients with severe insulin resistance.


Chemical Biology & Drug Design | 2007

Understanding the Mechanism of Action of the Novel SSAO Substrate (C7NH10)6(V10O28)·2H2O, a Prodrug of Peroxovanadate Insulin Mimetics

Francesc Yraola; Silvia Garcia-Vicente; Luc Marti; Fernando Albericio; Antonio Zorzano; Miriam Royo

A new vanadium salt, hexakis(benzylammonium) decavanadate (V) dihydrate (C7NH10)6(V10O28)·2H2O ( 1 ), has been synthesized as well as characterized chemically and biologically. An in vitro enzyme assay revealed that compound 1 is oxidized to the same extent as a combination of benzylamine and vanadate by the enzyme semicarbazide‐sensitive amine oxidase (SSAO), and therefore can be considered an SSAO substrate. It also stimulates glucose uptake in isolated rat adipocytes in a dose‐dependent manner. We describe here the results of 51V‐NMR experiments that, combined with the in vitro results, corroborate that compound 1 could act as a prodrug of di‐peroxovanadate ([V(OH)2(OO)2(OH)2]2−) insulin mimetics.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo

Eva Maria Novoa; Noelia Camacho; Anna Tor; Barrie Wilkinson; Steven James Moss; Patricia Marín-García; Isabel G. Azcárate; José M. Bautista; Adam C. Mirando; Christopher S. Francklyn; Sonia Varón; Miriam Royo; Alfred Cortés; Lluís Ribas de Pouplana

Significance Malaria remains one of the main health threats in the developing world, with staggering social and economic costs. Resistance to artemisins, the main pharmacological tool currently available against malaria, has been widely reported. Borrelidin, a natural compound that inhibits threonyl-tRNA synthetase, has long been studied for its antibacterial and antiparasitic properties, but undesirable toxic effects prevented its further clinical development. Here we present a group of borrelidin derivatives that retain their ability to inhibit Plasmodium threonyl-tRNA synthetase but not its human homolog. Furthermore, we demonstrate, for the first time to our knowledge, that these compounds are capable of effectively clearing a Plasmodium infection in animals, curing malaria with a potency equivalent to reference drugs such as chloroquine. Malaria remains a major global health problem. Emerging resistance to existing antimalarial drugs drives the search for new antimalarials, and protein translation is a promising pathway to target. Here we explore the potential of the aminoacyl-tRNA synthetase (ARS) family as a source of antimalarial drug targets. First, a battery of known and novel ARS inhibitors was tested against Plasmodium falciparum cultures, and their activities were compared. Borrelidin, a natural inhibitor of threonyl-tRNA synthetase (ThrRS), stands out for its potent antimalarial effect. However, it also inhibits human ThrRS and is highly toxic to human cells. To circumvent this problem, we tested a library of bioengineered and semisynthetic borrelidin analogs for their antimalarial activity and toxicity. We found that some analogs effectively lose their toxicity against human cells while retaining a potent antiparasitic activity both in vitro and in vivo and cleared malaria from Plasmodium yoelii-infected mice, resulting in 100% mice survival rates. Our work identifies borrelidin analogs as potent, selective, and unexplored scaffolds that efficiently clear malaria both in vitro and in vivo.


Tetrahedron Letters | 1988

Uteroglobin-like peptide cavities I. Synthesis of antiparallel and parallel dimers of bis-cysteine peptides

Mariano Ruiz-Gayo; Fernando Albericio; Miquel Pons; Miriam Royo; Enrique Pedroso; Ernest Giralt

Abstract Syntheses of parallel and antiparallel dimers of bis-cysteine peptides using four different protecting groups for the cysteine side chain are described.


Journal of Medicinal Chemistry | 2008

Structure−Activity Relationship of Kahalalide F Synthetic Analogues

Jose Carlos Jimenez; Àngel López-Macià; Carol Gracia; Sonia Varón; Marta Carrascal; Josep Maria Caba; Miriam Royo; Andrés Francesch; Carmen Cuevas; Ernest Giralt; Fernando Albericio

Kahalalide F (KF) is a natural product currently under phase II clinical trials. Here, we report the solid phase synthesis of 132 novel analogues of kahalalide F and their in vitro activity on a panel of up to 14 cancer cell lines. The structure-activity relationship of these analogues revealed that KF is highly sensitive to backbone stereotopical modification but not to side chain size modification. These observations suggest that this compound has a defined conformational structure and also that it interacts with chiral compounds through its backbone and not through its side chains. The N-terminal aliphatic acid appears to be a hydrophobic buoy in a membrane-like environment. Moreover, significant improvement of the in vitro activity was achieved.


European Journal of Medicinal Chemistry | 2014

Amphiphilic cationic carbosilane-PEG dendrimers: synthesis and applications in gene therapy.

Javier Sánchez-Nieves; Peter Fransen; Daniel Pulido; Raquel Lorente; M. Ángeles Muñoz-Fernández; Fernando Albericio; Miriam Royo; Rafael Gómez; F. Javier de la Mata

Here we synthesized carbosilane, generation 1 to 3, and PEG-based dendrons functionalized at the periphery with NHBoc groups and at the focal point with azide and alkyne moieties, respectively. The coupling of these two types of dendrons via click chemistry led to the formation of new hybrid dendrimers with two distinct moieties, the hydrophobic carbosilane and the hydrophilic PEG-based dendron. The protected dendrimers were transformed into cationic ammonium dendrimers. These unique amphiphilic dendrimers were studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells (PBMC) and their performance was compared with that of a PEG-free carbosilane dendrimer. The presence of the PEG moiety afforded lower toxicities and evidenced a weaker interaction between dendrimers and siRNA when compared to the homodendrimer analogous. Both features, lower toxicity and lower dendriplex strength, are key properties for use of these vectors as carriers of nucleic material.


Tetrahedron Letters | 2002

Undesired removal of the Fmoc group by the free ε-amino function of a lysine residue

Josep Farrera-Sinfreu; Miriam Royo; Fernando Albericio

Abstract In solid-phase peptide synthesis, a side-reaction consisting of the premature and undesired removal of the Fmoc group has been detected. This can be caused by a primary amine of sufficient basicity, such as the e-amino of the Lys, present in the peptide resin. This side-reaction, which is not promoted by either the β-amino side-chain of the Dapa residue or the α-amino group, can be prevented by a coupling/neutralization protocol in the case of Mtt protection or by a tandem deprotection–coupling reaction in the case of Alloc protection. The same kind of side-reaction has been detected when amino side-chain functions of Orn or Daba are free in the peptide resin.

Collaboration


Dive into the Miriam Royo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Miquel Pons

University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Francesc Yraola

École Polytechnique Fédérale de Lausanne

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Laia Crespo

University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge